Cambridge-based Owlstone Medical, which is developing its Breath Biopsy platform and offers applications in early disease detection and precision medicine, has appointed Mark Capone to its board as an independent non-executive director.

Capone has been a life sciences executive for 35 years and is president and chief executive of Precision Medicine Advisors. He was previously president and chief executive of Myriad Genetics which he transformed from a start-up to one of the largest precision medicine companies in the world. During his 17-year tenure, the company developed and launched more than a dozen reimbursed molecular diagnostics achieving annual revenues of more than $800 million. Before that, he spent 17-years at Eli Lilly and Company.

Capone is a non-executive board member of Abcam, Micoba Life Sciences, and NephroSant.

Billy Boyle, co-founder and chief executive of Owlstone Medical, said: “We are excited to welcome Mark Capone to the board at this important stage in our development. Mark is a recognised leader in the diagnostics industry who’s proven track record and deep commercial and corporate experience will be instrumental as we prepare to deploy Breath Biopsy into clinical settings for applications including lung cancer and liver disease.”

Capstone commented: “Owlstone Medical is poised to transform diagnostics through Breath Biopsy and I am very pleased to have been asked to help realise the vision of the team. I have been impressed with the potential of the platform, the progress made in high need clinical areas, and the passion and dedication of the leadership, and I look forward to helping drive the company’s success by supporting the development of their regulatory, reimbursement, and commercial strategy.”